ClinicalTrials.gg
Not yet recruitingNCT07947953LIORAUpdated Nov 19, 2026

A Prospective, Randomized, Placebo-Controlled Double Blind, 18 Month Study Evaluating the Efficacy and Tolerability of Lithium Orotate 10 mg Daily in Patients With Alzheimer's Disease and Mild Cognitive Impairment.

An observational study in Mild Cognitive Impairment and Dementia, sponsored by Koser, Robert B., MD PA. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Koser, Robert B., MD PA · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
200
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,422 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
111th of 271
200 · median 150
Started
2026
with 95 others
Observational
271 of 1,422
68 open now
Primary completion
2028-05
later than 321 of 431 live
Registered
1,422nd of 1,422
by date

Among the 1,422 studies in Cognitive Dysfunction with a site in United States, this one is the 111th largest by planned enrollment of the 271 observational ones that give a count, is one of 96 that started in 2026, is one of 271 observational ones, reaches primary completion later than 321 of the 431 other live ones, and was the 1,422nd registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

329 of the 1,422 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

324 more — sign in →

All 329 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,422 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized, placebo-controlled, double-blind clinical trial lasting 18 months. Participants will be randomized to 1:1 to Lithium Orotate or matching placebo. Double-blinding will be maintained for investigators, participants, and outcome assessors. An independent data monitoring committee will oversee safety. The study will utilize Lithium Orotate 5 mg twice daily. The U.S. Manufacturer is Nitricost. It is a synthetic, stable Lithium Salt. The Nutricost 5 mg capsules only contain Lithium Orotate. There is no Lithium Carbonate in the 5 mg product. The Lithium Carbonate is undesirable because it is sequestered in Amyloid Plaques. The Lithium Orotate has been shown to be resist degradation and sequestration by the Amyloid Plaques.

Recruitment is 6 months.

Treatment phase is 18 months. Follow up is 1 month for post treatment for safety.

Inclusion Criteria is adults aged 50-90 years; Diagnosis of probable Alzheimer's Disease (per NIA-AA criteria) or MCI (per Peterson criteria). Baseline MMSE score of 18-26 (for AD) or 24-30 (for MCI). Participants must be stable on approved AD medications (if applicable) for >3 months. Participants must provide informed consent (or via legally authorized representative).

Exclusion Criteria includes: Severe renal impairment of eGFR \<40, or CKD III-IV, History of Bipolar disorder or other lithium contraindications, Concomitant use of medications interacting with Lithium (e.g., diuretics, NSAIDs), Significant comorbidities (e.g., uncontrolled hypertension, recent stroke), Pregnancy or breastfeeding,

The Risk Benefit Ratio is extremely low. 1/100. The relative risk of using Lithium Orotate is extremely small compared to the possible significant benefits. The FDA has cleared the use of Lithium Orotate in this clinical trial.

The Sample Size is 200 participants (100 per arm), powered to detect a 2-point difference in MMSE change (SD=4, a+-=0.05, power=80%, 20% attrition). Stratification by AD/MCI status and age.

The Active Arm is Lithium Orotate capsules 10 mg orally daily. The Placebo Arm is Identical placebo capsules daily. Dosing of Lithium Orotate will be titrated down to 5 mg QD, if needed for tolerability. Compliance will be assessed via pill counts and patient diaries.

The Primary Endpoint is change in MMSE score from baseline, assessed every 3 months. Secondary Endpoint is PET Scan changes of Amyloid burden and/or Tau pathology at baseline and 18 months. PET Scans are optional only for participants that have an allergy to the PET Scan radionuclide, or have significant difficulty in transfers or transports to the imaging facility. Some participants will likely be home bound and unable to comply.

Safety and Incidence of adverse events (AEs), serious AEs and discontinuations will be monitored via common terminology criteria for adverse events (CTCAE).

Tolerability will be monitored via vital signs, renal functions (eGFR), thyroid function (TSH) and electrolyte panels every 3 months.

Read the detailed description

Every 3 months Participants will have MMSE, Safety labs, AE reporting. At each 3 month visit an assessment for side effects and safety will be noted in the body of the progress note under Objective. Every 3 months an MMSE will also be performed and compared with the last MMSE. If there is a 2 point change in MMSE, the study will be unblinded for those participants. These participants will be given the option to continue with the Lithium Orotate or change from Placebo to Lithium Orotate.

The Endpoint (18 months) will include MMSE, PET Scan all assessments.

Data Monitoring will include MMSE results (0 to 30) and Clock Drawing Test results (Pass or Fail) will be scanned into the Practice Fusion EMR. Nobody has access to the HIPPA protected information but myself and my staff. All participants will sign a HIPPA form. Practice Fusion is a Cloud-Based EMR that has an excellent reputation for secure privacy of patient information. The laboratory blood tests will be from Quest Laboratory which interfaces with Practice Fusion. If there is a significant drop in GFR or Hemoglobin, or an abnormal rise in Liver Function Tests, the trial will be suspended in those participants, and they will be referred back to their primary care doctor. Laboratory results will be discussed with the participant and HCS/POA during office visits every 3 months. The PET Scan results will be faxed to my office from Simon Med Imaging to my office and scanned into the EMR after they are discussed with the participant and HCS/POA, if present.

03

Conditions studied

  • Mild Cognitive Impairment and Dementia

Keywords

  • Lithium Orotate
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants having Alzheimer's Disease or Mild Cognitive Impairment

Eligibility criteria

Inclusion Criteria: Diagnosis of probable Alzheimer's Disease (per NIA-AA criteria) or Mild Cognitive Impairment (per Petersen criteria). Baseline score of 18-26 for AD or 24-30 for MCI. Stable on approved AD medications (if applicable) for >3 months. Ability to provide (or via legally authorized representative.

-

Exclusion Criteria: Severe renal impairment: \<40 mL/min, or CKD III-V. History of Bipolar disorder or other lithium (e.g., Hypothyroidism). Concomitant use of medications interacting with lithium (e.g., diuretics, NSAIDs). Significant comorbidities (e.g., uncontrolled Hypertension, recent Stroke). Pregnancy or breastfeeding.

-

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Placebo

    Placebo

  • Lithium Orotate 10 mg

    Lithium Orotate will be given to half the participants to see if it prevents or reverses cognitive decline in MCI or Alzheimer's patients.

06

What researchers measure

Primary outcomes

  1. 2 Point change in MMSE Scores. Clock Drawing Tests change pass to fail or vice versa.

    Every 3 months

    Time frame: 18 months

Secondary outcomes

  1. Amyloid changes on PET Scans with Centiloid Scores.

    Initial PET at onset of study and at end of study

    Time frame: 18 months

07

Study locations

1 site
  • Robert B Koser Md
    Bradenton, Florida 34209, United States
08

References and documents

Publications

  • Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res. 2013 Jan;10(1):104-7. doi: 10.2174/1567205011310010014. PubMed 22746245 ↗
  • Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76. PubMed 30947755 ↗
  • Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q. Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis. Eur Neurol. 2024;87(2):93-104. doi: 10.1159/000538846. Epub 2024 Apr 24. PubMed 38657568 ↗
  • Kessing LV, Gerds TA, Knudsen NN, Jorgensen LF, Kristiansen SM, Voutchkova D, Ernstsen V, Schullehner J, Hansen B, Andersen PK, Ersboll AK. Association of Lithium in Drinking Water With the Incidence of Dementia. JAMA Psychiatry. 2017 Oct 1;74(10):1005-1010. doi: 10.1001/jamapsychiatry.2017.2362. PubMed 28832877 ↗
  • Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, Hamplova SE, Lacey EK, Roche P, Yuan M, Hazaveh SS, Lee EA, Bennett DA, Yankner BA. Lithium deficiency and the onset of Alzheimer's disease. Nature. 2025 Sep;645(8081):712-721. doi: 10.1038/s41586-025-09335-x. Epub 2025 Aug 6. PubMed 40770094 ↗

Individual participant data

Plan to share: Yes — Journal of Nature. Neurology Reviews. American Family Physician. Journal of Family Practice.

Supporting information: Study protocol, Clinical study report

Time frame: Spring 2028

Access criteria: Website to be determined

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 18 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 18, 2026
Primary completionEst.
May 18, 2028
CompletionEst.
May 18, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947953
Lead sponsor
Koser, Robert B., MD PA
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
May 18, 2028 (estimated)
Completion
May 18, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

ROBERT B KOSER, MD
Contact
bluesinjector@yahoo.com
941-795-1135
ROBERT B KOSER, MD
Contact
bluesinjector54@gmail.com
941-348-0303
ROBERT B KOSER, MD
principal investigator · ROBERT B KOSER MD PA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion